“The biggest mistake dividend investors make is confusing a high-yield stock for a growing-yield stock,” advises a chief investment officer cited in today’s article. In order to separate out strong dividend growth stock picks from “accidental high-yielders”, the author screened for stocks sporting higher yields than the S&P 500 and with better forecasted dividend growth. For six dividend stocks that met these criteria, CLICK HERE.
When it comes to homebuilder stocks, the author of today’s article declares “What a difference a few months can make”: after plunging in the fourth quarter of last year due to concerns over rising interest rates and a possible recession, homebuilders have rallied this year. With valuations still relatively low despite the rally – and with the Fed now having signaled not to expect any rate hikes this year – homebuilder stocks appear to be attractive buys right now. For specific homebuilder stocks to consider based on their implied upside potential, CLICK HERE.
If you’re not familiar with the reverse wealth effect you might want to become familiar with it, as it may be a pivotal factor in driving down stock and real estate prices going forward. For more on the reverse wealth effect, how bad it could get this time around – and what investors with both short-term and long-term investment horizons can do to protect themselves from this phenomenon – CLICK HERE.
Activist hedge fund ADW Capital has recently taken up a position in a micro-cap that it believes the market is significantly underpricing and which, thanks to its organic growth prospects and underrated CEO, the fund’s team believes “is in the early innings of creating monumental shareholder value.” For the micro-cap in question, which ADW believes could see a more than 30x increase in its price, CLICK HERE.
“While the risk of dividend cuts is out there, there are ways to minimize the number of dividend cuts and also to reduce their impact on the overall dividend income,” advises the author of today’s article. He outlines several key metrics that strategic dividend growth investors may want to consider in that regard – and what he looks for in each metric based on his years of experience (and lessons learned from the sting of dividend cuts). For more, CLICK HERE.
Low-priced stocks offer smaller investors the chance to not only make a tidy profit (as these stocks can provide the largest short-term gains), but also to acquire a higher share count than they would be able to of large and mega-cap stocks. Today’s article highlights five stocks trading under $10 that possess solid upside potential based on price targets from Goldman Sachs. For these five stocks – which may be especially appealing to more aggressive traders – CLICK HERE.
“The energy sector has been whipsawed by headlines lately, and many investors can’t decide whether to buy or sell oil stocks,” notes the author of today’s article. So should energy investors be shopping or selling? The author examines the state of fracking stocks, oil service stocks and the major oil companies and comes up with what he believes is the likely answer. For more, CLICK HERE.
“What goes up must come down” is a law of physics – and it’s also the basis of the trade idea outlined in today’s article. Specifically, this trade applies the “what goes up must come down” rule to market volatility, with the author noting that volatility mean reversion is “a predictable pattern that we can take advantage of as options traders.” For more on this trade that can be used to profit from market volatility (which there has been plenty of recently!), CLICK HERE.
Biotech investors may be missing out on some very lucrative drugs and therapies. As today’s article notes, while “It is common for large-cap biotech investments…to feature exposure to companies working on treatments for well-known diseases…the growing unmet medical needs universe is going, well, mostly unmet by traditional biotech investments.” Case in point: Non-alcoholic steatohepatitis (NASH) – a potentially fatal liver disease affecting upwards of 16 million Americans and for which there is currently no approved drug therapy. So how can biotech investors access the opportunity presented by NASH and other unmet medical needs? CLICK HERE.
While the material that the company highlighted in today’s article produces has increased in price by 20% this year, the company has seen its stock price fall by double digits since the beginning of the year. So is this stock – which pays an attractive dividend – a buy? The author looks at why the shares of this company (and other producers of this material) have been driven down despite the fact that business is good – and why this could represent an opportunity for investors. For more, CLICK HERE.